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Objective: To compare the safety and efficacy of dabigatran to warfarin for the treatment of 
deep vein thrombosis and pulmonary embolism.
Background: Venous thromboembolism (VTE) is a disease comprised of two conditions: deep 
vein thrombosis and pulmonary embolism. VTE is a major cause of morbidity and mortality 
worldwide with an annual incidence estimated at 1–3 cases per 1,000 individuals. This incidence 
increases with age from 0.1 per 1,000 in adolescence to eight per 1,000 in those 80 years of 
age and older. As the proportion of patients 65 years of age and older expands, the number 
of patients presenting with VTE will also increase. Anticoagulation remains the cornerstone 
of VTE treatment. Traditionally, vitamin K antagonists have been used to minimize the risk of 
thrombus extension and for secondary prevention. Unpredictable pharmacokinetics and pharma-
codynamics, routine monitoring, drug–food and drug–drug interactions, and potentially severe 
adverse events have all been cited as barriers to optimal care. Dabigatran has been proposed as 
a suitable alternative to warfarin therapy in the treatment of VTE. Therefore, a critical appraisal 
of dabigatran’s safety and efficacy is necessary to determine its role in therapy.
Conclusion: Dabigatran remains an alternative to warfarin therapy for the treatment of VTE. 
However, dabigatran also has distinct disadvantages that warrant consideration. Clinicians 
must ensure that drug characteristics align with patient characteristics to optimize patient 
outcomes.
Keywords: venous thromboembolism, pulmonary embolisms, venous thrombosis, anticoagu-
lants, warfarin sodium, dabigatran etexilate mesylate
Introduction
Venous thromboembolism (VTE) is a disease comprised of two conditions: deep 
vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot most 
often found affecting areas of stasis within the veins of the lower leg or thigh, 
whereas PE occurs when part of a clot detaches, travels, and lodges in the pul-
monary arteries, causing a potentially fatal condition.1 VTE is a major cause of 
morbidity and mortality worldwide with an annual incidence estimated at 1–3 cases 
per 1,000 individuals.2,3 This incidence increases with age from 0.1 per 1,000 in 
adolescence to eight per 1,000 in those 80 years of age and older.2–4 In Europe and 
the United States, death attributed to VTE is thought to exceed 400,000 annually.5,6 
As the proportion of patients 65 years of age and older expands, the number of 
patients presenting with VTE will also increase.4 Therefore, timely identification 
and aggressive treatment is essential to reducing morbidity and mortality associ-
ated with this disease.
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Risk factors, clinical presentation, and 
diagnosis
Several risk factors for developing VTE have been extensively 
studied and identified (Table 1).7–11 Patients with a prior history 
of VTE and/or those who have cancer are at particularly high 
risk of developing DVT and progressing to PE.12 Likewise, 
orthopedic procedures, trauma, and hypercoagulability disor-
ders have also been linked to an increased incidence of VTE.4,12 
Despite extensive knowledge pertaining to the precipitating 
factors for VTE, early detection remains challenging.
VTE symptoms are generally nonspecific and often 
require objective tests for proper diagnosis.13 Discomfort 
in the calf muscle on passive dorsiflexion of the foot, also 
known as Homans’ sign, was once considered the key clinical 
indicator of DVT. This sign has since fallen out of favor as it 
is present in less than one-third of patients with confirmed 
DVT, it is found in more than 50% of patients without DVT, 
and it may pose a risk for embolization.14 Instead, clinicians 
should review complaints of leg pain, swelling, edema, or 
tenderness on palpation.15 Other symptoms of DVT may 
include redness, unexplained fever, increased visibility of 
skin veins, or bluish discoloration.
Progression to PE occurs in approximately 50% of 
untreated proximal DVT cases.12 Patients with PE typically 
present with sudden-onset chest pain, shortness of breath, 
tachypnea, and tachycardia. PE is a life-threatening condition 
and may result in cardiopulmonary collapse.16 For these 
reasons, quick identification of VTE is crucial.
Radiographic contrast studies remain the gold standard 
for the diagnosis of DVT (venography) and PE (pulmonary 
angiography). However, their utility in clinical practice is lim-
ited. The invasive nature of the studies and need for contrast 
agents, particularly in critically-ill patients, may pose more 
risk than benefit.13 Radiographic contrast studies are also sig-
nificantly more expensive than the available alternatives. Less 
invasive tests, such as compression ultrasound, ventilation–
perfusion scan, and computed tomography scans are more 
commonly used in clinical practice for the initial evaluation 
of suspected VTE.17
Treatment strategies
Anticoagulation remains the cornerstone of VTE treatment. 
Once the diagnosis of VTE has been confirmed, anticoagulant 
therapy should begin. Treatment can be divided into two 
phases: 1) rapid initiation to minimize the risk of thrombus 
extension; and 2) maintenance for secondary prevention.18 
Phase 1, or the acute stage of VTE treatment, is generally 
7 days and requires rapidly acting anticoagulants such as 
unfractionated heparin, low-molecular-weight heparin 
(LMWH), and fondaparinux.15 The maintenance phase fea-
tures continued anticoagulation, traditionally with a vitamin 
K antagonist (VKA), intended to reduce the risk of long-term 
sequelae (ie, post-thrombotic syndrome).15 This second phase 
of therapy allows the body to slowly dissolve the clot via 
endogenous thrombolytic processes.
The optimal duration of therapy varies. Patients may con-
tinue on anticoagulant therapy beyond 3 months, depending 
on the clot’s etiology and site. Patient risk factors pertaining 
to clotting as well as bleeding will also need to be assessed 
prior to treatment.15 In life- or limb-threatening situations, 
anticoagulation may be insufficient. Elimination of the 
obstructing thrombus may be necessary, and the use of 
thrombolysis or thrombectomy can be considered.15
As beneficial as anticoagulants have proven to be in 
the treatment of VTE, they also come with substantial risk. 
The anticipation surrounding the development of the target-
specific oral anticoagulants (TSOACs), including dabigatran, 
rivaroxaban, apixaban, and edoxaban, has stemmed from 
the challenges that typically accompany VKA therapy. 
Unpredictable pharmacokinetics and pharmacodynamics, 
routine monitoring, drug–food and drug–drug interactions, 
and potentially severe adverse events have all been cited 
as barriers to optimal care.19 Dabigatran has been proposed as 
a suitable alternative to warfarin therapy in the treatment of 
Table 1 vTe risk factors
Strong risk factors
 Fracture (hip or leg)
 Hip or knee replacement
 Major general surgery
 Major trauma
 Spinal cord injury
 History of vTe
Moderate risk factors
 Central venous lines
 Chemotherapy
 Congestive heart or respiratory failure
 Hormone replacement therapy
 Cancer
 Oral contraceptives
 Paralytic stroke
 Pregnancy, postpartum
 Thrombophilia
weak risk factors
 Bed rest .3 days
 increasing age (.60 years)
 Obesity (BMi over 30 kg/m2)
 Pregnancy, antepartum
 varicose veins
Notes: with kind permission from Springer Science+Business Media: Frederick 
AA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 
107(23 Suppl i):9–16.34
Abbreviations: vTe, venous thromboembolism; BMi, body mass index.
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VTE. A critical appraisal of dabigatran’s safety and efficacy 
is necessary to determine its role in therapy.
Dabigatran characteristics
Dabigatran was first approved by the European Commission 
and the US Food and Drug Administration (FDA) to reduce 
the risk of stroke and systemic embolism in patients with 
nonvalvular atrial fibrillation in 2008 and 2010, respectively. 
Dabigatran has since been approved for the treatment and 
prevention of recurrence of DVT and PE in the USA and 
Europe, with availability in over 100 countries. Dabigatran 
is a specific, competitive, and reversible direct thrombin 
inhibitor. Thrombin enables the conversion of fibrinogen into 
fibrin during the coagulation cascade. Thus, dabigatran’s inhi-
bition of thrombin prevents clot formation. Unlike  warfarin, 
dabigatran only elicits an effect on one factor within the 
coagulation cascade, possibly allowing for a more predictable 
pharmacokinetic profile.20
Pharmacokinetic and pharmacodynamic 
properties
Another differentiating characteristic of dabigatran is its 
formulation. Formulated as a prodrug, dabigatran etexilate 
requires hydrolysis for conversion to the active moiety. 
Dabigatran etexilate is also dependent on an acidic environ-
ment for consistent and predictable absorption. For this rea-
son, the drug is applied to a tartaric acid core, which is then 
encapsulated (Figure 1). The tartaric acid core provides 
a stable acidic environment, making the formulation less 
dependent on gastrointestinal acidity.
Dabigatran has less drug–drug interactions than  warfarin; 
however, drug concentrations can be influenced by the 
activity of P-glycoprotein transporters. These efflux pumps 
prevent the absorption of dabigatran etexilate and propel 
the drug back into the intestinal lumen. Drugs that induce 
or inhibit P-glycoprotein transporters may affect dabigatran 
plasma concentrations (Table 2). Finally, dabigatran is pri-
marily excreted via the kidney (∼80%). As a result, dabigatran 
exposure is increased in patients with renal impairment, 
which correlates with the severity of the disease.20,21
Special considerations
The lack of routine monitoring with dabigatran is a distinct 
advantage over VKAs. However, there are special consider-
ations with dabigatran that are worth noting. Dabigatran has a 
relatively short half-life (∼12 hours) requiring twice-daily dos-
ing.22 Therefore, careful attention to adherence with dabigatran 
is required. Without routine monitoring to assist in identifying 
nonadherent patients, clinicians will need to educate and inform 
patients regarding the increased risk of stroke associated with 
poor adherence. Dabigatran has a quick onset of action as it 
achieves maximum serum concentration (C
max
) in 1 hour.22 
While this can be advantageous, it also means that there is a 
very short duration of action. This may expose a nonadherent 
patient to unnecessary risk if not taken properly.
Urgent reversal options for dabigatran include hemodialy-
sis, charcoal, antifibrinolytics, and coagulation factor replace-
ment.23 While each of these options has their own respective 
advantages and disadvantages, the clinical utility of each 
remains in question. For example, although hemodialysis can 
decrease dabigatran levels by 60%–70%, it requires central 
venous access.23 Fortunately, a reversal agent for dabigatran 
is in development. Idarucizumab is a humanized monoclonal 
antibody fragment that has a 350 times higher affinity for 
Dabigatran etexilate (DE)
Tartaric acid core
Esterases
Circulation
•  DE = dabigatran etexilate
•  D = dabigatran
•  DG = dabigatran glucuronides
•  PGP = P-glycoprotien transporter
DE PGP
Enterocyte
DE
Lumen Key:
DE
DE
DG
Liver
Kidney
D
D
Figure 1 D characteristics (absorption, distribution, metabolism, excretion).
Note: Reproduced from Risk versus benefit of non-vitamin K dependent 
anticoagulants compared to warfarin for the management of atrial fibrillation in the 
elderly. Circulation. 2013;30(7):513–525, Ogbonna KC, Jeffery SM.28
Table 2 inhibitors and inducers of P-glycoprotein
inhibitors
 Amiodarone
 Ketoconazole/itraconazole
 Clarithromycin/erythromycin
 verapamil
 Diltiazem
 Quinidine
 Protease inhibitors
 Sirolimus/tacrolimus
inducers
 Rifampicin
 St John’s wort
 Carbamazepine
 Phenytoin
Note: Data from Fenner et al.35
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dabigatran than thrombin. Thus far, no immunogenic reac-
tions have been observed.23 In early 2015, using interim data 
from an ongoing Phase III study,24 Boehringer Ingelheim 
(Ingelheim, Germany) submitted applications for approval 
to the European Medicines Agency, US FDA, and Health 
Canada.25 The US FDA has designated idarucizumab as a 
“Breakthrough Therapy”, which will allow for an accelerated 
approval pathway.4
Dabigatran offers a promising alternative to traditional 
oral anticoagulant therapy based on its pharmacokinetic and 
pharmacodynamic characteristics. It is, however, important 
to evaluate clinical trials investigating the safety and efficacy 
of dabigatran in the prevention and treatment of VTE.
VTE trial data
Phase i: acute treatment of vTe
RE-COVER (number [n] =2,564) and RE-COVER II 
(n=2,589) evaluated dabigatran for the acute treatment of 
VTE.26,27 Both trials used a randomized, double-blind, double-
dummy design to compare a fixed dose of dabigatran (150 mg 
twice daily) with dose-adjusted warfarin (international nor-
malized ratio [INR]: 2.0–3.0) for a 6-month period (Table 3). 
Initial parenteral anticoagulation was administered for at least 
5 days in each study. The primary outcome for both trials was 
symptomatic and objectively verified recurrent VTE or related 
death (ie, fatal PE). Dabigatran was found to be  noninferior 
in the reduction of recurrent VTE when compared to  warfarin 
in RE-COVER (2.4% vs 2.1%, respectively; hazard ratio 
[HR] =1.10; 95% confidence interval [CI]: 0.65–1.84) and 
RE-COVER II (2.3% vs 2.2%, respectively; HR =1.08; 95% 
CI: 0.64–1.80).26,27 Additionally, rates of bleeding were similar 
between dabigatran and warfarin in each trial (RE-COVER 
[1.6% vs 1.9%, respectively; HR =0.82; 95% CI: 0.45–1.48] 
and RE-COVER II [1.2% vs 1.7%, respectively; HR =0.69; 
95% CI: 0.36–1.32]).26,27 While all other adverse effects were 
similar between the groups, patients receiving dabigatran in 
the RE-COVER study were more likely to experience dys-
pepsia compared with patients receiving warfarin (2.9% vs 
0.6%, respectively; P,0.001), likely due to its formulation 
with the tartaric acid core.26,28
RE-COVER II was initiated after the completion of the 
original RE-COVER study due to low rates of recurrent 
VTE.27 The ability to combine the data from both studies 
allows for robust interpretation and confirmation of the 
original results of RE-COVER. The additional study provided 
an expanded pool of subjects that was more in line with the 
general VTE population with the number of patients with 
DVT, PE, and both DVT and PE, representing approximately 
69%, 23%, and 9%, respectively, of the trial population.26,27 
Pooled analysis of the 5,107 patients from RE-COVER and 
RE-COVER II maintained noninferiority for the primary 
efficacy outcome (2.4% vs 2.2%, respectively; HR =1.09; 
95% CI: 0.76–1.57) and similar rates of major bleeding (1.4% 
vs 2.0%; HR =0.73; 95% CI: 0.48–1.11).
Table 3 Clinical trials with dabigatran in the treatment of vTe
Trial RE-COVER RE-COVER II RE-MEDY RE-SONATE
Characteristics
 Design Double-blind; noninferiority Double-blind; noninferiority Double-blind;  
noninferiority
Double-blind; 
superiority
 n (patients) 2,539 2,568 2,856 1,343
 intervention Heparin $5 days followed by  
DAB 150 mg BiD
Heparin $5 days followed by  
DAB 150 mg BiD
DAB 150 mg BiD DAB 150 mg 
BiD
 Control Heparin $5 days and dose- 
adjusted warfarin (iNR: 2.0–3.0)
Heparin $5 days and dose- 
adjusted warfarin (iNR: 2.0–3.0)
Dose-adjusted warfarin  
(iNR: 2.0–3.0)
Placebo
 intended duration 6 months 6 months 18 months 6 months
 TTR (%) 60 57 64 NA
Results – efficacy: VTE or VTE-related/unexpected death
 Hazard ratio 1.10 1.08 1.44 0.08
 (95% Ci) (0.65–1.84) (0.64–1.80) (0.78–2.64) (0.02–0.25)
 P-value for Noninferiority ,0.001 Noninferiority ,0.001 Noninferiority 0.014 Superiority 
,0.001
Results – safety: clinically relevant or major bleeding
 Hazard ratio 0.63 0.62 0.54 2.92
 (95% Ci) (0.47–0.84) (0.45–0.84) (0.41–0.71) (1.52–5.60)
 P-value 0.002 0.001 ,0.001 0.0013
Note: Data from Schulman et al,26 Schulman et al,27 and Schulman et al.29
Abbreviations: vTe, venous thromboembolism; n, number; DAB, dabigatran; BiD, twice daily; iNR, international normalized ratio; TTR, time in therapeutic range; NA, not 
applicable; CI, confidence interval.
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Phase ii: extended treatment of vTe
Extended treatment of VTE with dabigatran was studied in two 
separate trials, RE-MEDY and RE-SONATE.29 RE-MEDY 
compared the noninferiority of dabigatran 150 mg twice daily 
vs dose-adjusted warfarin (INR: 2.0–3.0), while RE-SONATE 
compared the superiority of the same dose of dabigatran vs 
placebo. Patients in both trials had objectively confirmed 
symptomatic proximal DVT or PE and completed at least 3 
months of treatment with warfarin or dabigatran.
In the RE-MEDY trial, dabigatran demonstrated noninfe-
riority compared with warfarin for the primary efficacy end-
point of recurrent, objectively confirmed, symptomatic VTE or 
VTE-related death (HR =1.44; 95% CI: 0.78–2.64) (Table 3).29 
Major bleeding was considerably lower with dabigatran when 
compared with warfarin; however, it did not achieve statistical 
significance (P=0.06). There was, however, an increased risk 
of acute coronary syndrome (ACS) in patients randomized 
to dabigatran (0.9% vs 0.2%; P=0.02), furthering concerns 
observed in previous trials.29,30
In the RE-SONATE trial (dabigatran vs placebo) dabigatran 
demonstrated a significant reduction (92%) in the primary 
endpoint of objectively confirmed symptomatic VTE or unex-
pected death, representing superiority over placebo (HR =0.08; 
95% CI: 0.02–0.25).29 While major bleeding alone was not 
significantly increased with dabigatran, the composite of major 
or clinically relevant nonmajor bleeding was significantly 
increased with dabigatran (HR =2.92; 95% CI: 1.52–5.60). 
The risk of “any bleeding” was also significantly increased 
with dabigatran use (HR =1.82; 95% CI: 1.23–2.68). Despite 
the increased risk of ACS observed in the RE-MEDY trial, there 
was no difference between the two groups in RE-SONATE. This 
may again speak to the protective effects of warfarin and less 
so to the harmful effects of dabigatran, as a similar finding was 
observed in dabigatran’s atrial fibrillation studies.27–30
Special populations
Older adults
The incidence of VTE and recurrent VTE increases with 
age and older adults are at a higher risk for death from PE.3 
Furthermore, the risk of bleeding associated with treatment is 
higher in this population as well.3 The advent of TSOACs is 
promising in this group of individuals because of the increased 
potential for drug–drug interactions with warfarin and the 
need for frequent monitoring. However, dabigatran is highly 
dependent on renal elimination, which can be problematic 
considering renal impairment is common in the elderly due to 
age-related changes in renal function and the high prevalence 
of chronic kidney disease. This may lead to a greater risk 
of bleeding in the elderly, particularly those with poor renal 
function. The use of dabigatran in the elderly is not well estab-
lished, as this population has been underrepresented in clinical 
trials. This is especially true for those $75 years of age.
The mean age for patients in RE-COVER and RE-
COVER II was ,60 years, and only 10.4% of the population 
was $75 years of age.26,27 Despite the small sample of elderly 
patients, subgroup analyses found no difference between the 
efficacy of dabigatran and warfarin. However, a meta-analysis 
found dabigatran to be associated with a greater risk (relative 
risk [RR] =0.91 95% confidence interval [CI] [0.36–2.26]) 
of major bleeding in subjects $75 years of age compared to 
apixaban and rivaroxaban (RR =0.23 95% CI [0.08–0.69]; 
RR =0.27 [0.13–0.59, respectively].3 Although the overall 
trial results with dabigatran showed a reduced risk of major 
bleeding with dabigatran when compared to warfarin, there 
appears to be a greater risk of major bleeding in those $75 
years of age. Additional studies in this population are war-
ranted to determine the role of dabigatran in the elderly.
Renal impairment
While dabigatran offer several advantages over warfarin, 
the safety and efficacy of dabigatran in patients with renal 
impairment is a concern. Dabigatran significantly depends 
on renal elimination (80% of total clearance), much more so 
than the other TSOACs.22 Pharmacokinetic data shows a 3.2-
fold increase in the area under the curve (AUC) for patients 
with moderate renal impairment (creatinine clearance [CrCl]: 
30–50 mL/minute), while a 6.3-fold increase in the AUC 
was found using pharmacokinetic modeling.22 Moderate 
renal impairment increases the C
max
 and half-life minimally, 
so no additional dose adjustment is recommended for those 
individuals; however, severe renal impairment has a profound 
effect on C
max
 and half-life.22 Of note, this was the basis for the 
75 mg twice-daily dose for stroke prophylaxis in patients with 
atrial fibrillation and a CrCl of 15–30 mL/minute, but this 
dose has not been evaluated in clinical trials. Currently, there 
are no dosing recommendations for dabigatran when used for 
VTE prevention or treatment in patients with CrCl ,30 mL/
minute.22 Due to the paucity of data in this subset of patients, 
the manufacturer recommends avoiding dabigatran in patients 
with CrCl ,30 mL/minute.22
Although individuals with severe renal impairment 
(CrCl ,30 mL/minute) have been excluded from clinical 
trials with all of the TSOACs, we can draw some fundamen-
tal conclusions from enrolled subjects with mild–moderate 
renal impairment. A subgroup analysis of subjects with reduced 
renal function (CrCl #50 mL/minute) found a lower risk of 
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VTE recurrence with dabigatran compared to warfarin, but this 
was not statistically significant (RR =0.11; 95% CI: 0.01–1.88).3 
Of note, apixaban and rivaroxaban appear to be associated with 
an increased risk in recurrence in patients with reduced renal 
function.3 Despite the small sample, the risk of major bleeding 
was 7.2 times higher in subjects with a CrCl #50 mL/minute 
compared to subjects with a CrCl .50 mL/minute.3 Note the 
risk of major bleeding with warfarin was only 2.9 times higher 
in those with a CrCl #50 mL/minute.3
Cancer
Cancer is an independent risk factor for VTE and 20% of all 
VTEs occur in individuals with cancer.31 The pathophysiol-
ogy is multifactorial, often involving pre-existing risk factors 
(eg, obesity, age) and cancer-specific risk factors (eg, the 
type of cancer, chemotherapy). The recommended long-term 
treatment for VTE in cancer patients is LMWH because of its 
superior efficacy over warfarin.32 However, not all patients 
are candidates for LMWH, especially if they have severe 
renal impairment or if it is the patient’s preference not to 
perform daily injections. While warfarin is a reasonable 
alternative, it has many disadvantages. Thus, the TSOACs are 
appealing since these agents are administered orally instead 
of via subcutaneous injection.
None of the TSOACs, including dabigatran, have been 
studied exclusively in patients with active cancer. Those with 
cancer were, however, allowed to enroll in RE-COVER and 
RE-COVER II, but only 8% of the population from each trial 
had cancer.26,27 Furthermore, the eligibility criteria for patients 
with cancer were relatively broad and included patients with 
recurrent/metastatic cancer, a cancer diagnosis, or any treat-
ment for cancer, in the 5 years preceding study enrollment. 
RE-MEDY and RE-SONATE also had similar numbers of 
patients with active cancer at baseline.29 Although there were 
no differences between dabigatran and warfarin in the sub-
groups of cancer patients for each of these trials, no concrete 
conclusions can be made due to the small number of patients. 
Additionally, warfarin is not the preferred option in patients 
with cancer, so it is unknown how dabigatran would compare 
with LMWH.32 Current guidelines do not recommend any of 
the TSOACs for either the prevention or treatment of VTE 
in patients with cancer.32 Future studies are warranted and 
should compare the efficacy and safety of dabigatran with 
LMWH since it is now the standard of care.
Role in therapy
Dabigatran has similar efficacy when compared to warfa-
rin for the treatment of VTE. Although dabigatran offers 
convenience and fewer drug–drug interactions when 
compared to warfarin, these attributes are offset by adher-
ence concerns and the lack of a reversal agent. Utilization 
in special populations must also be carefully considered, 
as dabigatran’s use in renal impairment, cancer, and for 
patients .65 years of age requires further investigation.
Dabigatran’s bleeding profile is comparable to that of 
warfarin; however, key differences exist. For example, dab-
igatran is associated with a lower incidence of intracranial 
hemorrhage; this may be offset by the increased rate of 
gastrointestinal bleeding and concern for ACS. In the first 
quarter of 2011, the Institute for Safe Medication Practices 
(ISMP) identified 932 serious adverse drug events attributed 
to dabigatran.33 Of the 932 adverse drug events identified, 
293 were further classified as gastrointestinal hemorrhage. 
The ISMP elaborated further by highlighting elderly patients’ 
predisposition to hemorrhagic complications with dabigatran 
therapy. The median age for dabigatran case reports dur-
ing this quarter was 80 years compared to a median age of 
56 years for all other drugs,33 further emphasizing the need 
for assessment of individual patient characteristics and pre-
existing conditions prior to therapy selection.
Another disadvantage is the need for parenteral anti-
coagulation for 5–10 days before dabigatran initiation. 
Rivaroxaban and apixaban have both been studied as an 
initial treatment for acute VTE without the need to wait 5 days 
prior to starting therapy. This caveat to dabigatran therapy 
may dissuade its use in the acute treatment of VTE.
Conclusion
Dabigatran remains an alternative to warfarin for the treat-
ment of VTE. Selection of this therapy may be appropriate for 
those patients unable to tolerate the requirements of warfarin 
management. Patient characteristics, as well as cost, will need 
to be considered on a case-by-case basis. The therapeutic 
armament for the treatment of VTE has increased consid-
erably over the last 5 years. Despite the available options, 
clinicians must ensure that the drug characteristics align with 
patient characteristics to optimize patient outcomes.
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